TAI UGBE: Open Payments
NPI 1750967261 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$513 in 28 payments from 9 companies in 2025. Trend: 2023 $366 · 2024 $750 · 2025 $513
Food & beverage: $503Education: $10
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 14 | $207 |
| Neurocrine BioSciences, Inc. | 4 | $103 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $56 |
| Janssen Pharmaceuticals, Inc | 2 | $41 |
| Lundbeck LLC | 1 | $28 |
| Alkermes, Inc. | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
Products named: VRAYLAR, INGREZZA, CAPLYTA, REXULTI, INVEGA SUSTENNA, ARISTADA, TRINTELLIX, INVEGA.
Industry payments across TX — which companies pay providers there.
